|
|
|
| home > ebr > winter 2003 > peptides in metabolic diseases - peptidomics as a comprehensive profiling tool |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
| The genotype represents a blueprint of an organism, which is used in different ways during development, adulthood and disease states. Quantitative changes in the use of genes contribute to the variability of general physiology and pathophysiology. A mutation of a gene qualitatively changes the genotype and thus may determine a predisposition for a disease. However, peptides and proteins define the actual phenotype and may reflect or even cause a pathogenic process. Therefore proteomics is regarded as a pivotal technology in defining the transition from health to disease, describing the current disease status and its progression with time. In this context, it has to be distinguished between technologies addressing proteins in general and those specifically analysing peptides. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Imke Schulte, Metabolic Syndrome Project Research Manager, Hartmut Selle, Biomarker Discovery Project Research Manager, and Peter Schulz-Knappe, CSO and Co-founder of BioVisioN
Having graduated from the University Mьnster in Biochemistry, Imke Schulte worked on molecular and cellular physiology for her doctoral thesis at the Medical School in Hannover. In 2002 she joined BioVisioN as a Project Manager, working in the medical research department with responsibility for projects in the field of the metabolic syndrome.
Hartmut Selle graduated as a Biologist from the University of Hannover in Germany. He worked as a Clinical Research Assistant for the pharmaceutical industry conducting clinical trials on disorders of the CNS, the vascular system and the gastrointestinal tract. In 1999 he joined BioVisioN as a Project Manager and has been involved in a number of projects on biomarker discovery, including Alzheimer's disease.
Peter Schulz-Knappe is one of four founders of BioVisioN. He holds a Medical degree from the University of Heidelberg, and a degree in Cell Biology from the Medical School in Hannover. He has over 20 years experience in peptide chemistry and functional analysis of peptides. As CSO he is responsible for the scientific work in the company.
|
|
|
|
|
|
 |
Industry Events |
 |
5th Annual BioPharma Asia Convention 2012
19-22 March 2012, Marina Bay Sands, Singapore
BioPharma Asia Convention is the only event that brings together senior level executives from global and regional pharma companies, biotechs, CMOs, CROs, academic institutions, investors and all other industrial stakeholders to assess the latest industrial trends, partnership models and solutions in Asia.
More info >> |
|
 |
News and Press Releases |
 |
More safety in drug packaging
In Germany like in the rest of the world, child safety in drug packaging is an issue that has not been properly solved yet. Today, Faubel, the custom label supplier based in Melsungen, provides a safe and economical solution consisting of an innovative safety label which can be affixed to the back of a tablet blister pack like an ordinary sticker.
More info >> |
|
|
